Back to Agenda
Session 8: FDA’s New IND Safety Reporting Guidance and What It Means for Sponsors Today
Session Chair(s)
Scott Janiczak, PharmD, MPH
Team Leader, Division of Pharmacovigilance-I, OSE, CDER, FDA, United States
In December 2025, FDA finalized its guidance for industry regarding Sponsor responsibilities for safety reporting requirements and safety assessment for investigational new drug (IND) studies. This guidance provides an overview of the FDA’s IND safety reporting requirements and includes, among other information, recommendations for the development of safety surveillance plans and considerations for aggregate data analyses as required by the IND safety reporting provisions (§§ 312.32(c)(1)(i)(C) or 312.32(c)(1)(iv)). In this session, representatives from FDA will provide an overview of the guidance, highlight key updates and discuss recommendations to help sponsors comply with these requirements. Additionally, representatives from Industry will provide real-world perspectives on translating the guidance into an operational framework for evaluating accumulating safety data across clinical development programs. Attendees will leave with strategies to develop process efficiencies and optimize overall compliance with IND safety reporting requirements.
Learning Objective :
At the conclusion of this session, participants should be able to:
- Understand FDA expedited safety reporting and updated aggregate analysis approaches
- Communicate serious safety risks while preserving trial integrity
- Identify key elements of an aggregate safety surveillance strategy
- Integrate blinded and unblinded aggregate analyses through independent review
Have an account?